A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-22

Study Completion Date

2026-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double blinded, controlled phase I clinical study. To evaluate the safety and immunogenicity of receiving two doses of MVA strain monkeypox attenuated live vaccine in individuals aged 18 years and above.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox

NCT05740982

Monkeypox

COMPLETED PHASE2

Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections

NCT06549530

Monkeypox (Mpox)

ACTIVE_NOT_RECRUITING PHASE2

Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®

NCT01827371

Smallpox

COMPLETED PHASE2

A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigational Monkeypox Vaccines

NCT05988203

Monkeypox

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine

NCT05512949

Monkeypox

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double blinded, controlled phase I clinical study. The study plans to recruit 120 participants aged 18 years and above. The experimental vaccine MVA strain monkeypox attenuated live vaccine has two different doses (low dose and high dose). The ratio of low-dose experimental group, high-dose experimental group, and placebo group is 1:1:1. Participants will be divided into three groups: healthy individuals, men who have sex with men, and HIV infected individuals, with a ratio of 2:1:1. Different groups will be divided into individuals with a history of vaccination against smallpox and those without a history of immunization, based on whether each population has a history of vaccination against smallpox. Each participant will receive one dose of the experimental vaccine or placebo on day 0 and day 28, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Monkeypox

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group 1

Participants without a history of immunization against smallpox

Group Type EXPERIMENTAL

MVA strain monkeypox attenuated live vaccine (low dose)

Intervention Type BIOLOGICAL

Low dose MVA strain monkeypox attenuated live vaccine

Experimental group 2

Participants without a history of immunization against smallpox

Group Type EXPERIMENTAL

MVA strain monkeypox attenuated live vaccine (high dose)

Intervention Type BIOLOGICAL

High dose MVA strain monkeypox attenuated live vaccine

Experimental group 3

Participants with a history of immunization against smallpox

Group Type EXPERIMENTAL

MVA strain monkeypox attenuated live vaccine (low dose)

Intervention Type BIOLOGICAL

Low dose MVA strain monkeypox attenuated live vaccine

Experimental group 4

Participants with a history of immunization against smallpox

Group Type EXPERIMENTAL

MVA strain monkeypox attenuated live vaccine (high dose)

Intervention Type BIOLOGICAL

High dose MVA strain monkeypox attenuated live vaccine

Control group 1

Participants without a history of immunization against smallpox

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Vaccine excipient

Control group 2

Participants with a history of immunization against smallpox

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Vaccine excipient

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MVA strain monkeypox attenuated live vaccine (low dose)

Low dose MVA strain monkeypox attenuated live vaccine

Intervention Type BIOLOGICAL

MVA strain monkeypox attenuated live vaccine (high dose)

High dose MVA strain monkeypox attenuated live vaccine

Intervention Type BIOLOGICAL

Placebo

Vaccine excipient

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* On the day of enrollment, individuals aged 18 years or older with a history of smallpox vaccination must have been born before 1980;
* Can provide legal proof of identity;
* Be able to understand the experimental procedure and sign a written informed consent form, expressing agreement to participate in the experiment;
* Be able to participate in all planned follow-up visits and comply with all trial procedures (such as completing diary/contact cards and being able to return for visits);
* On the day of enrollment, the body temperature was less than 37.3 ℃ (axillary temperature);
* Men and women of childbearing age who have no plans to have children within 6 months and agree to take effective contraceptive measures within 6 months after receiving the experimental vaccine.

Exclusion Criteria

* Individuals with a history of smallpox, monkeypox, or close contact with monkeypox in the past;
* Individuals who are allergic to any ingredients of eggs, vaccines, or substances used in production processes, or have a history of other severe allergies;
* Use immunoglobulin and/or any blood products within 3 months prior to administering the trial vaccine, or plan to use them during the trial period;
* Currently using salicylate drugs or planning long-term use during the trial period;
* Have used any experimental or unregistered products within one month prior to administering the trial vaccine, or plan to use them during the trial period;
* Administer inactivated vaccine within 14 days before administering the experimental vaccine or attenuated live vaccine within 30 days before administering the experimental vaccine;
* Chronic disease patients are in the acute or progressive phase of chronic disease;
* Long term use of immunosuppressants or other immunomodulatory drugs within 6 months prior to vaccination with the experimental vaccine;
* Having undergone chemotherapy or radiation therapy or organ and bone marrow transplantation related treatments for cancer or other diseases;
* Diseases or medical measures that lead to immune dysfunction, such as congenital immunodeficiency, organ and bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma or malignant tumors, etc;
* Moderate or severe acute illness/infection, or febrile illness on the day of vaccination;
* Individuals with a history of thrombocytopenia or other coagulation disorders may be contraindicated for subcutaneous injection;
* Suffering from serious cardiovascular disease, serious liver and kidney disease, and diabetes that cannot be controlled by drugs;
* Previous history of mental or neurological disorders or family history;
* Currently suffering from various infectious, suppurative, and allergic skin diseases;
* Women of childbearing age: pregnant or lactating, or with a positive blood pregnancy test;
* Plan to move before the end of the trial or leave the local area for a long time during the scheduled trial visit;
* Abnormal blood routine, blood biochemistry, urine routine, electrocardiogram or heart disease related indicators before vaccination (except for minor abnormalities judged by doctors to have no clinical significance);
* Researchers believe that any situation that may affect the evaluation of the experiment;
* Active tuberculosis patients;
* For HIV infected individuals, the plasma HIV-1 RNA level during screening should be ≥ 200 copies/mL, or positive test for hepatitis B, hepatitis C and syphilis;
* For healthy people and men and women who have sex with each other, hepatitis B, hepatitis C, syphilis and HIV) are positive;
* Individuals who experience severe allergic reactions after the first dose of vaccination;
* Serious adverse events that are definitely related to the first dose of vaccination;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes